Last updated: May 30, 2026
Omniscan (gadoversetamide) suppliers: What companies make and supply the drug in the US and globally?
Omniscan is the brand name for gadoversetamide (a gadolinium-based MRI contrast agent). The supplier landscape is split between marketing authorization holders (MAHs) and manufacturers of the drug substance/drug product, with additional upstream supply for contrast-agent formulation components and sterile fill-finish.
Who manufactures Omniscan (gadoversetamide) and supplies the finished drug product?
Finished drug product manufacturing for Omniscan is typically performed by specialty sterile injectable plants under contract, with the MAH coordinating product release and regulatory compliance for each market.
Key upstream pattern for sterile MRI contrast agents
- Drug substance supply: gadolinium chelate intermediates produced by specialty chemical manufacturers.
- Drug product manufacturing: compounding, sterile filtration/fill, container closure integrity controls, aseptic processing, and batch release testing.
- Global logistics: temperature-controlled distribution and batch-level traceability.
What suppliers provide gadoversetamide drug substance used to make Omniscan?
For gadolinium chelates used in contrast agents, supply is usually concentrated among manufacturers of Gd-chelate intermediates and controlled purity materials that meet contrast-agent specs (particle-free, chelate integrity, residual metals, and tight impurity limits). These suppliers are often not the same entity that performs the sterile fill-finish.
Which companies supply the sterile fill-finish and packaging for Omniscan?
Sterile fill-finish and packaging are frequently handled by:
- Aseptic sterile fill-finish CDMOs (cartridges/syringes/vials depending on market presentation).
- Cold-chain logistics providers supporting contrast-agent distribution.
What is the Orange Book status of Omniscan, and does that affect supplier availability?
Omniscan is a hospital-administered sterile injectable product with IP and regulatory status managed via FDA listings where applicable. Orange Book status is relevant primarily to generic small-molecule oral drugs; contrast agents are typically governed by a mix of NDC labeling, FDA registration, and device/drug manufacturing controls. Supplier availability is more constrained by sterility manufacturing capacity and CMC regulatory approvals than by Orange Book-type exclusivity alone.
When do Omniscan exclusivity or patent protections expire, and how does that impact supply?
Supply expansion for sterile injectables usually hinges on:
- Regulatory approvals for competing products (including CMC equivalency).
- Commercial manufacturing capacity and validated aseptic processes for gadolinium chelates.
Which generics or biosimilars compete with Omniscan, and who supplies them?
Omniscan is not a biologic, so biosimilars do not apply. Competition is typically via:
- Generic gadoversetamide formulations if approved/marketed in relevant jurisdictions.
- Alternative gadolinium contrast agents (different active ingredients) that may substitute in procurement.
How do Omniscan procurement contracts typically allocate supplier risk?
Hospital and distributor procurement commonly contracts around:
- Batch release reliability and pharmacovigilance support.
- Continuity-of-supply terms tied to sterile manufacturing slots.
- Recall readiness and traceability.
What distribution suppliers (wholesalers) move Omniscan in the US?
US distribution is typically through the major pharmaceutical wholesale/distribution networks, which handle:
- Product receipt and lot tracking
- Cold-chain or controlled-condition transport
- Allocation management during supply constraints
How does Omniscan supply chain compare with other gadolinium MRI contrast agents?
Relative supply-chain constraints for gadolinium contrast agents usually reflect:
- Specialized chelate production
- Sterile injectables fill-finish capacity
- Batch release testing demands
Key Takeaways
- Omniscan sourcing is structured around (1) MAH responsibility, (2) drug substance supply for gadoversetamide chelate, (3) sterile fill-finish and packaging, and (4) distributor networks.
- Competitive entry is driven more by CMC and sterile manufacturing capacity than by Orange Book-style exclusivity mechanics.
- Supplier diversification for gadolinium contrast agents is typically limited by validated aseptic manufacturing and chelate-spec impurity controls.
FAQs
-
Is Omniscan made by the same company worldwide?
Sourcing often differs by market due to local MAH and licensed manufacturing sites.
-
Are there CDMOs that commonly fill-finish MRI gadolinium contrast agents?
Yes. Aseptic sterile fill-finish CDMOs specialize in sterile injectable manufacturing for contrast products.
-
Does Omniscan face shortages like other gadolinium agents?
Supply constraints can occur when aseptic capacity, chelate supply, or regulatory release bottlenecks tighten.
-
Can distributors substitute Omniscan with other gadolinium contrast agents?
Procurement substitution depends on formulary rules, dosing equivalency, and clinical/contract preferences.
-
What determines whether a generic gadoversetamide can be supplied at scale?
It depends on validated CMC, impurity and chelate integrity specs, and sterile fill-finish throughput.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
- FDA. Drug Manufacturing and Product Quality. https://www.fda.gov/drugs/manufacturing-human-drugs
